148 related articles for article (PubMed ID: 27449794)
21. Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus.
Marasini N; Ghaffar KA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Curr Drug Deliv; 2017; 14(5):701-708. PubMed ID: 27440071
[TBL] [Abstract][Full Text] [Related]
22. Novel platform technology for modular mucosal vaccine that protects against streptococcus.
Zaman M; Ozberk V; Langshaw EL; McPhun V; Powell JL; Phillips ZN; Ho MF; Calcutt A; Batzloff MR; Toth I; Hill GR; Pandey M; Good MF
Sci Rep; 2016 Dec; 6():39274. PubMed ID: 27976706
[TBL] [Abstract][Full Text] [Related]
23. Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice.
Dunn LA; McMillan DJ; Batzloff M; Zeng W; Jackson DC; Upcroft JA; Upcroft P; Olive C
Vaccine; 2002 Jun; 20(21-22):2635-40. PubMed ID: 12034087
[TBL] [Abstract][Full Text] [Related]
24. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
25. Structure-Activity Analysis of Cyclic Multicomponent Lipopeptide Self-Adjuvanting Vaccine Candidates Presenting Group A
Madge HYR; Sharma H; Hussein WM; Khalil ZG; Capon RJ; Toth I; Stephenson RJ
J Med Chem; 2020 May; 63(10):5387-5397. PubMed ID: 32347723
[TBL] [Abstract][Full Text] [Related]
26. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines.
Moyle PM; Dai W; Zhang Y; Batzloff MR; Good MF; Toth I
Bioconjug Chem; 2014 May; 25(5):965-78. PubMed ID: 24712905
[TBL] [Abstract][Full Text] [Related]
27. Structure-activity relationship of group A streptococcus lipopeptide vaccine candidates in trimethyl chitosan-based self-adjuvanting delivery system.
Nevagi RJ; Dai W; Khalil ZG; Hussein WM; Capon RJ; Skwarczynski M; Toth I
Eur J Med Chem; 2019 Oct; 179():100-108. PubMed ID: 31247372
[TBL] [Abstract][Full Text] [Related]
28. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
[TBL] [Abstract][Full Text] [Related]
29. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
30. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
31. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
[TBL] [Abstract][Full Text] [Related]
32. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model.
Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L
Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476
[TBL] [Abstract][Full Text] [Related]
33. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
Batzloff MR; Yan H; Davies MR; Hartas J; Lowell GH; White G; Burt DS; Leanderson T; Good MF
J Infect Dis; 2005 Oct; 192(8):1450-5. PubMed ID: 16170764
[TBL] [Abstract][Full Text] [Related]
34. Polyethylenimine quantity and molecular weight influence its adjuvanting properties in liposomal peptide vaccines.
Dai CC; Huang W; Yang J; Hussein WM; Wang J; Khalil ZG; Capon RJ; Toth I; Stephenson RJ
Bioorg Med Chem Lett; 2021 May; 40():127920. PubMed ID: 33705898
[TBL] [Abstract][Full Text] [Related]
35. Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.
Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J
PLoS One; 2017; 12(4):e0175707. PubMed ID: 28414746
[TBL] [Abstract][Full Text] [Related]
36. Moving forward: a mucosal vaccine against group A streptococcus.
Georgousakis MM; McMillan DJ; Batzloff MR; Sriprakash KS
Expert Rev Vaccines; 2009 Jun; 8(6):747-60. PubMed ID: 19485755
[TBL] [Abstract][Full Text] [Related]
37. Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine.
Zaman M; Skwarczynski M; Malcolm JM; Urbani CN; Jia Z; Batzloff MR; Good MF; Monteiro MJ; Toth I
Nanomedicine; 2011 Apr; 7(2):168-73. PubMed ID: 21034860
[TBL] [Abstract][Full Text] [Related]
38. Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant.
Azmi F; Ahmad Fuaad AA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Bioorg Med Chem; 2014 Nov; 22(22):6401-8. PubMed ID: 25438764
[TBL] [Abstract][Full Text] [Related]
39. Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation.
Moyle PM; Olive C; Ho MF; Burgess M; Karpati L; Good MF; Toth I
J Org Chem; 2006 Sep; 71(18):6846-50. PubMed ID: 16930036
[TBL] [Abstract][Full Text] [Related]
40. Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy.
Pandey M; Sekuloski S; Batzloff MR
Immunol Cell Biol; 2009 Jul; 87(5):391-9. PubMed ID: 19417770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
